Subscribe To
Eisai and biogen's lecanemab: a flawed treatment for alzheimer's disease
lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. ...
December 30, 2022, 5:22 pm
Biogen's alzheimer's drug likely to be approved with warning labels
A new as-yet-unreported death among those taking Biogen's lecanemab in an extended post-Phase 3 study h...
December 29, 2022, 1:41 pm
Experimental drug lecanemab may be a landmark breakthrough in battle against alzheimer's
Yahoo Finance's Anjalee Khemlani discusses positive news around an Alzheimer's drug, plus reports that China is considering a fourth round of COVID va...
November 30, 2022, 1:44 pm
5 things to know about the new alzheimer's drug — including why it may be risky for people who take blood thinners
Shares of Eisai and Biogen did not move dramatically after the drug companies reported the full results of the clinical trial for their experimental A...
November 30, 2022, 11:38 am
Biogen's (biib) lecanemab shows benefit but with side effects
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the earl...
November 30, 2022, 10:32 am
Biib stock alert: what the latest alzheimer's drug data means for biogen
Biogen (NASDAQ: BIIB ) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. According to a p...
November 30, 2022, 10:00 am
Biogen stock up 3% premarket after update on alzheimer's treatment; stifel reiterates buy rating
Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimenta...
November 30, 2022, 6:48 am
Biogen and eisai strengthen lead in alzheimer's drug race. the stocks are rising.
Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of ...
November 30, 2022, 5:11 am
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm
Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...
November 20, 2022, 6:30 pm